PAR-101/OPT-80

· Optimer Pharmaceuticals LLC (a subsidiary of Merck & Co.)

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for PAR-101/OPT-80, covering 2011-07-29 to 2011-07-29. Get the full timeline:

Most recent: Clinical Trial Update: PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) [Phase 3]